What is Opdivo (nivolumab), and what does it treat?
Opdivo (generic name nivolumab) is an immunotherapy drug that targets the PD-1 pathway. By blocking PD-1, it helps the immune system recognize and attack cancer cells. It is used across multiple cancer types, and specific indications depend on the country and on whether Opdivo is given alone or combined with other treatments.
How does Opdivo work?
Opdivo blocks PD-1, a checkpoint on immune cells. When PD-1 is active, immune cells can become less able to attack tumors. Blocking PD-1 can restore immune activity against cancer.
How is Opdivo given (IV schedule)?
Opdivo is administered by intravenous infusion. The exact dose and frequency depend on the cancer type and whether it’s used as monotherapy or in combination with other drugs.
What side effects do patients ask about?
Common side effects reported with PD-1 checkpoint inhibitors include fatigue, skin reactions, diarrhea or constipation, nausea, decreased appetite, and flu-like symptoms. Because Opdivo activates immune responses, it can also cause immune-related inflammation in organs (for example the lungs, colon, liver, endocrine glands, or skin). These immune-related effects can be serious and require prompt medical attention and treatment adjustments.
What happens if someone misses a dose or delays treatment?
Delays can reduce treatment effectiveness, but the right next step depends on why the dose was missed and on how advanced the therapy schedule is. Clinicians typically reassess timing and whether supportive care, dose adjustments, or additional monitoring are needed—especially if side effects are ongoing.
Is Opdivo used with other immunotherapies or chemotherapy?
Opdivo is used both alone and in combination regimens in some cancers. Combination therapy can change the dosing schedule and the side-effect profile compared with Opdivo alone.
Who should be cautious with Opdivo?
Patients often need extra evaluation if they have autoimmune disease, have received a transplant, have had prior severe immune-related reactions to checkpoint inhibitors, or have significant organ inflammation already. Clinicians also monitor closely for endocrine problems, liver inflammation, lung inflammation, and other immune-related complications.
How long does treatment usually last?
Treatment duration varies by indication and response. Some patients continue therapy for a fixed period; others may receive treatment until disease progression or unacceptable toxicity, depending on the regimen and the prescribing guidance.
Is there an Opdivo alternative or biosimilar?
Whether an alternative can replace Opdivo depends on the specific cancer indication, line of therapy, and local availability. Options may include other PD-1/PD-L1 inhibitors or different checkpoint strategies, but switching is a clinical decision based on evidence for that exact cancer type and patient situation.
What should patients know before starting?
Before starting Opdivo, clinicians typically review prior therapies, current symptoms, baseline organ function (including liver and thyroid testing), and any history of autoimmune disease or organ inflammation. During treatment, patients are instructed to report new or worsening symptoms quickly because immune-related side effects can develop during therapy.
Sources
No sources were provided with your message, so I can’t cite specific claims. If you share where you want the information from (for example, the Opdivo prescribing information you’re using, a country-specific label, or a link), I can produce a cited, label-accurate summary.